Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass shares are trading at $5.89, near their 52-week high of $6.88 and well above the $1.33 low touched last year. Recent analyst activity underscores the bullish sentiment. Craig-Hallum initiated ...

PLEASANTON, Calif., May 2, 2023 /PRNewswire/ -- Veeva Systems (VEEV) (NYSE: VEEV) today announced the addition of Veeva Compass Prescriber and Veeva Compass National to its current Veeva Compass ...